This grand round has already taken place.
In this seminar we use a mouse model and human studies of p53 to show that an African-specific genetic variant of p53 called Y107H is defective for tumor suppression. We show that we can identify anti-cancer drugs that are preferentially cytotoxic to Y107H tumor cells. And we use Y107H as a way to highlight the p53 target gene PADI4, which citrullinates tumor antigens, as critical for tumor suppression by p53.
Dates and Times
Start: 6/1/2023 12:00 AM
End: 6/1/2023 7:00 PM
1. Understand the role of p53 in tumor suppression
2. Understand the difference between a mutant form of p53 in cancer, and a cancer-predisposing ‘hypomorph’ of p53
3. Understand the role of the p53 target gene PADI4 in tumor suppression and immune recognition of cancer
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.
Please contact the Grand Round coordinator listed below: